Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ironwood Pharmaceuticals (IRWD) Cash & Equivalents: 2010-2025

Historic Cash & Equivalents for Ironwood Pharmaceuticals (IRWD) over the last 16 years, with Sep 2025 value amounting to $140.4 million.

  • Ironwood Pharmaceuticals' Cash & Equivalents rose 59.17% to $140.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $140.4 million, marking a year-over-year increase of 59.17%. This contributed to the annual value of $88.6 million for FY2024, which is 3.90% down from last year.
  • Ironwood Pharmaceuticals' Cash & Equivalents amounted to $140.4 million in Q3 2025, which was up 51.22% from $92.9 million recorded in Q2 2025.
  • Over the past 5 years, Ironwood Pharmaceuticals' Cash & Equivalents peaked at $740.3 million during Q1 2023, and registered a low of $88.2 million during Q3 2024.
  • In the last 3 years, Ironwood Pharmaceuticals' Cash & Equivalents had a median value of $108.5 million in 2025 and averaged $169.4 million.
  • Its Revenue - Interest and Investment Income has fluctuated over the past 5 years, first skyrocketed by 201.01% in 2010, then dropped by 19.55% in 2011.
  • Over the past 3 years, Ironwood Pharmaceuticals' Revenue - Interest and Investment Income (Quarterly) stood at -$298.3 million in 2009, then skyrocketed by 201.01% to $301.4 million in 2010, then decreased by 19.55% to $272.0 million in 2011.
  • Its Cash & Equivalents was $140.4 million in Q3 2025, compared to $92.9 million in Q2 2025 and $108.5 million in Q1 2025.